Ligand-gated ion channel

NMDA receptor

N-methyl-D-aspartate receptor

  • GeneGRIN1
  • FamilyIonotropic glutamate receptors

The NMDA receptor was first cloned in 1991, from the rat. The single protein encoded by the cDNA forms a receptor-channel complex with the electrophysiological and pharmacological properties of the NMDA receptor. Its sequence resembles that of the AMPA and kainate receptors, with four putative transmembrane segments after a large extracellular domain. Its messenger RNA is found in neurons throughout the brain, particularly in the hippocampus, cerebral cortex and cerebellum.1 Seven subunits are known today, the GluN1 subunit, four GluN2 subunits (GluN2A to GluN2D) and two GluN3 subunits (GluN3A and GluN3B). All subtypes of the receptor are thought to combine two copies of the obligatory GluN1 subunit with two copies of GluN2 and/or GluN3 subunits.2 Further subunits were cloned in 1992. In the rat, the subunits NR2A, NR2B and NR2C gave typical glutamate- and NMDA-activated currents only together with NR1, and NR1-NR2A and NR1-NR2C channels differed in gating and magnesium sensitivity. In the mouse, the subunits ε2 and ε3 formed channels with ζ1 that differed in their affinities for agonists, their sensitivity to competitive antagonists and their block by magnesium. The ε2 messenger RNA was found only in the forebrain and the ε3 messenger RNA mainly in the cerebellum.3,4

The NMDA receptor differs from other ligand-gated ion channels in five ways. Its channel is blocked by magnesium in a voltage-dependent manner, it is highly permeable to calcium, it has slow kinetics because glutamate unbinds slowly, its activation needs a co-agonist (glycine or D-serine) besides glutamate, and it has an array of modulatory sites.2 Receptors with GluN2A or GluN2B subunits open with high conductance, are strongly blocked by magnesium and are highly permeable to calcium. Receptors with GluN2C or GluN2D subunits have a lower conductance, are less sensitive to magnesium and are less permeable to calcium.2

In mice without the NR1 (GluN1) subunit, the NMDA-induced rises in intracellular calcium and membrane currents were abolished, so no other subunit can replace it. The mice died 8 to 15 hours after birth, and pathological findings suggested respiratory failure as the cause, although the overall neuroanatomy of the brain looked normal. The loss of NR1 also lowered the level of NR2B, but not of NR2A.5

Dysfunction of the NMDA receptor is involved in neurological and psychiatric disorders, among them stroke, pathological pain, neurodegenerative diseases and schizophrenia. In schizophrenia a reduced presence or activity of the receptor is suggested, probably in inhibitory GABAergic neurons. In anti-NMDA receptor encephalitis, antibodies lower the density of the receptors.2

In cats and rats, ketamine and phencyclidine blocked the excitation of spinal neurones by N-methyl-aspartate and had little effect on excitation by quisqualate and kainate. The same selective block occurred when ketamine (2.5 to 20 mg/kg) and phencyclidine (0.2 to 0.5 mg/kg) were given intravenously. The authors suggested that the reduced excitation through NMDA receptors contributes to the anaesthetic and analgesic properties of both drugs. The anticonvulsant MK-801 blocked NMDA-evoked current in rat neocortical neurons in culture, and it was effective only when applied together with NMDA, which fits an open-channel block.6,7 A review calls ketamine a non-competitive antagonist at the NMDA receptor, which is central to learning and memory because of its role in synaptic plasticity. Ketamine also blocks muscarinic acetylcholine receptors, may strengthen GABA inhibition, induces the release of dopamine and acts as a weak agonist at mu opioid receptors.8 Ketamine is an open channel blocker of NMDA receptors. The discovery of its rapid antidepressant effects in patients with depression and treatment-resistant depression led to new treatments for mood disorders, and the US Food and Drug Administration approved esketamine in 2019.9

Recreational use of ketamine has increased in many parts of the world. A major physical harm is ulcerative cystitis, which seems particularly associated with chronic, frequent use. Frequent daily use is associated with neurocognitive impairment and most robustly with deficits in working and episodic memory. Many frequent users are concerned about addiction and report trying but failing to stop.8

Sources (9)
  1. Moriyoshi et al. 1991Moriyoshi K, Masu M, Ishii T, et al. (1991) Molecular cloning and characterization of the rat NMDA receptor Nature
  2. Paoletti et al. 2013Paoletti P, Bellone C, Zhou Q (2013) NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease Nat Rev Neurosci
  3. Monyer et al. 1992Monyer H, Sprengel R, Schoepfer R, et al. (1992) Heteromeric NMDA receptors: molecular and functional distinction of subtypes Science
  4. Kutsuwada et al. 1992Kutsuwada T, Kashiwabuchi N, Mori H, et al. (1992) Molecular diversity of the NMDA receptor channel Nature
  5. Forrest et al. 1994Forrest D, Yuzaki M, Soares HD, et al. (1994) Targeted disruption of NMDA receptor 1 gene abolishes NMDA response and results in neonatal death Neuron
  6. Anis et al. 1983Anis NA, Berry SC, Burton NR, et al. (1983) The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate Br J Pharmacol
  7. Huettner et al. 1988Huettner JE, Bean BP (1988) Block of N-methyl-D-aspartate-activated current by the anticonvulsant MK-801: selective binding to open channels Proc Natl Acad Sci U S A
  8. Morgan et al. 2012Morgan CJ, Curran HV, Independent Scientific Committee on Drugs (2012) Ketamine use: a review Addiction
  9. Krystal et al. 2024Krystal JH, Kavalali ET, Monteggia LM (2024) Ketamine and rapid antidepressant action: new treatments and novel synaptic signaling mechanisms Neuropsychopharmacology

Binding affinity (Kᵢ)

13 substances, 17 displayed values. Strongest first within each organism. The bar is pKᵢ on a log scale. Open a row to see the assay and every report behind the value.

Pig

4 measurements
  • Dizocilpine3.4 nMTemme et al. 2018
    Assay
    porcine brain membranes, [3H]PCP displacement (PCP binding site)
    Shown value from
    Temme et al. 2018, Table 1
    Error
    ± 0.80 SD
  • PCP99 nMTemme et al. 2018
    Assay
    Pig brain cortex membranes; [3H](+)-MK-801 competition at the NMDA PCP binding site
    Shown value from
    Temme et al. 2018, Table 1, PCP-site affinity column
    Error
    ± 19 SEM, n = 3
  • Memantine740 nMTemme et al. 2018
    Assay
    Pig brain cortex membranes; [3H](+)-MK-801 competition at the NMDA PCP binding site
    Shown value from
    Temme et al. 2018, Table 1, PCP-site affinity column
    Error
    ± 74 SEM, n = 3
  • Dextromethorphan3400 nMTemme et al. 2018
    Assay
    Pig brain cortex membranes; [3H](+)-MK-801 competition at the NMDA PCP binding site
    Shown value from
    Temme et al. 2018, Table 1, PCP-site affinity column
    Error
    ± 800 SEM, n = 3

Rat

13 measurements
  • Dizocilpine3.0 nMWong et al. 1988 · 2 reports
    Assay
    rat cerebral cortical membranes; [3H]MK-801 (2 nM) displacement
    Shown value from
    Wong et al. 1988, Table 2
  • Diphenidine18 nMWallach et al. 2016
    Assay
    Rat forebrain homogenate; (+)-[3H]MK-801 competitive binding at the NMDA PCP site
    Shown value from
    Wallach et al. 2016, Table 1
    Error
    ± 2.2 SEM, n = 4
  • 3-MeO-PCP20 nMRoth et al. 2013
    Assay
    NIMH PDSP 12-point radioligand binding concentration-response at the NMDA PCP/MK-801 site
    Shown value from
    Roth et al. 2013, Table 2
  • PCPrange incl. untraced22 nMColestock et al. 2018 · 5 reports
    Assay
    Rat forebrain homogenate; (+)-[3H]MK-801 competitive binding at the NMDA PCP site
    Shown value from
    Colestock et al. 2018, Table 3
    Range
    22–59 nM in 5 reports
    Error
    ± 1.6 SEM, n = 3
    Sources and values behind the range, same assay family
    ReportValueWhere
    Wallach et al. 201658 nMTable 1, PCP reference row
    Colestock et al. 201822 nMTable 3
    Roth et al. 201359 nMTable 2
    Wong et al. 198842 nM, 52 nMTable 2
  • Methoxphenidine36 nMWallach et al. 2016
    Assay
    Rat forebrain homogenate; (+)-[3H]MK-801 competitive binding at the NMDA PCP site
    Shown value from
    Wallach et al. 2016, Table 1
    Error
    ± 3.7 SEM, n = 4
  • 3-MeO-PCE61 nMRoth et al. 2013
    Assay
    NIMH PDSP 12-point radioligand binding concentration-response at the NMDA PCP/MK-801 site
    Shown value from
    Roth et al. 2013, Table 2
  • Ephenidine66 nMKang et al. 2017
    Assay
    whole rat brain homogenate; (+)-[3H]MK-801 displacement, 100 µM glutamate and 10 µM glycine
    Shown value from
    Kang et al. 2017, Results, Receptor binding data
    Error
    ± 3.7 SEM, n = 3
  • Methoxetamine259 nMRoth et al. 2013
    Assay
    NIMH PDSP 12-point radioligand binding concentration-response at the NMDA PCP/MK-801 site
    Shown value from
    Roth et al. 2013, Table 2
  • Memantineunresolved378 nMWallach et al. 2016 · 2 reports
    Assay
    Rat forebrain homogenate; (+)-[3H]MK-801 competitive binding at the NMDA PCP site
    Shown value from
    Wallach et al. 2016, Table 1
    Range
    378–2500 nM in 2 reports
    Error
    ± 26 SEM, n = 4

    Reported values disagree and no value is established. 2 reports in all, 378–2500 nM.

    Sources and values behind the range, same assay family
    ReportValueWhere
    Wallach et al. 2016378 nMTable 1
    Rammes et al. 20012500 nMTable 1
  • Ketamineunresolved659 nMRoth et al. 2013 · 5 reports
    Assay
    NIMH PDSP 12-point radioligand binding concentration-response at the NMDA PCP/MK-801 site
    Shown value from
    Roth et al. 2013, Table 2
    Range
    324–1930 nM in 5 reports

    Reported values disagree and no value is established. 5 reports in all, 324–1930 nM.

    Sources and values behind the range, same assay family
    ReportValueWhere
    Wallach et al. 2016324 nMTable 1
    Roth et al. 2013659 nMTable 2
    Wong et al. 19881090 nM, 1930 nMTable 2
    Rammes et al. 2001500 nMTable 1
  • Ibogaine3200 nMSweetnam et al. 1995
    Assay
    rat cortex, [3H]MK-801 displacement
    Shown value from
    Sweetnam et al. 1995, Table 3 (Sweetnam)
  • Dextromethorphanother reports differ5000 nMGorman et al. 1997 · 2 reports
    Assay
    rat forebrain synaptic membranes, [3H]MK-801 displacement, non-competitive site
    Shown value from
    Gorman et al. 1997, Table 1
    Range
    800–5000 nM in 2 reports
    Error
    ± 300 SEM, n = 2

    This is the best-supported value. Other reports differ. 2 reports in all, 800–5000 nM.

  • Methadoneother reports differ8300 nMGorman et al. 1997 · 2 reports
    Assay
    rat forebrain synaptic membranes, [3H]MK-801 displacement, non-competitive site
    Shown value from
    Gorman et al. 1997, Table 1
    Range
    2500–8300 nM in 2 reports
    Error
    ± 1200 SEM, n = 2

    This is the best-supported value. Other reports differ. 2 reports in all, 2500–8300 nM.

Also reported to act here

Substances reported to act here, without a displayed value.

Values are published numbers in nM per organism. Different assays, species and receptor preparations are not directly interchangeable, and a value does not establish clinical potency or safety.